Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2024 | Story Anthony Mthembu | Photo Supplied
Melanie Ridgard
Melanie Ridgard celebrates receiving a Master of Business Administration (MBA) at the graduation ceremony held at the UFS Bloemfontein campus on 19 April 2024.

In the realm of self-development, few stories are as inspiring as that of Melanie Ridgard, the Interim Administration and Events Coordinator at the South African Research Chair in Industrial Development (SARChI-ID) at the University of Johannesburg (UJ). Ridgard’s forthcoming graduation with a Master in Business Administration (MBA) on 19 April 2024 from the University of the Free State (UFS) marks not only a personal triumph but also a testament to the transformative power of higher education.

Reflecting on her journey, Ridgard shares, “This moment signifies a culmination of rigorous studying, dedication and perseverance in mastering business fundamentals, leadership skills and strategic thinking.” Her pursuit of an MBA stemmed from a pivotal moment in her career when she was promoted at the Centre for Teaching and Learning (CTL) at UFS. Tasked with leading a group of young people Ridgard recognised the need to augment her knowledge to effectively guide her colleagues. The MBA became her vehicle for professional growth, extending beyond a mere qualification to a profound transformation of her leadership capabilities.

“Attaining an MBA milestone represents a transformative experience that has shaped my thinking to make impactful contributions in any future landscape,” Ridgard explains. Her experience not only enhanced her strategic acumen but also deepened her understanding of organisational dynamics. She acknowledges the pivotal role played by the UFS Business School in nurturing her journey towards academic and personal success.

What to expect from Ridgard

Looking ahead, Ridgard’s commitment to continuous learning remains unwavering. Selected as one of five MBA students to address the 17th International Business Conference (IBC) in September 2024, she eagerly anticipates the opportunity to share insights on her work titled, “Next-Gen Integration: Navigating the Onboarding Maze for Gen Z in Today's Workplace.” Despite her current responsibilities at UJ, she harbors plans to pursue a PhD in the near future.

Amidst her ambitious pursuits, Ridgard remains grounded, prioritising the celebration of her MBA achievement. ‘’As everyone dreams about it, I just want to walk over that stage in a black gown and a hood on my head with my loved ones cheering me on,’’ she shared.

Ridgard’s journey serves as a beacon of inspiration, exemplifying the transformative potential of education and the enduring impact of determined leadership. Her story reminds us that true leadership is not merely about reaching milestones but also about empowering others and embracing continuous growth. 

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept